Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC. Abushahin F, et al. Among authors: lurain jr. Gynecol Oncol. 2008 Jan;108(1):53-7. doi: 10.1016/j.ygyno.2007.08.062. Epub 2007 Sep 27. Gynecol Oncol. 2008. PMID: 17904208
FIGO stage IIIC endometrial carcinoma: prognostic factors and outcomes.
Hoekstra AV, Kim RJ, Small W Jr, Rademaker AW, Helenowski IB, Singh DK, Schink JC, Lurain JR. Hoekstra AV, et al. Among authors: lurain jr. Gynecol Oncol. 2009 Aug;114(2):273-8. doi: 10.1016/j.ygyno.2009.04.013. Epub 2009 May 9. Gynecol Oncol. 2009. PMID: 19428094
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
Cowan M, Swetzig WM, Adorno-Cruz V, Pineda MJ, Neubauer NL, Berry E, Lurain JR, Shahabi S, Taiym D, Nelson V, O'Shea KL, Kocherginsky M, Matei D. Cowan M, et al. Among authors: lurain jr. Gynecol Oncol. 2021 Oct;163(1):57-63. doi: 10.1016/j.ygyno.2021.08.005. Epub 2021 Aug 18. Gynecol Oncol. 2021. PMID: 34419285 Clinical Trial.
Evaluation of Outcomes in Patients With Carcinoma of the Cervix Treated With Concurrent Radiation and Cisplatin Versus Cisplatin/5-FU Compared With Radiation Alone.
Donnelly ED, Refaat T, Gentile M, Herskovic A, Boyle J, Helenowski I, Rademaker A, Lurain J, Schink J, Singh D, Strauss JB, Small W Jr. Donnelly ED, et al. Among authors: lurain j. Am J Clin Oncol. 2015 Oct;38(5):437-41. doi: 10.1097/COC.0b013e3182a1b448. Am J Clin Oncol. 2015. PMID: 24022364 Clinical Trial.
Low-Dose-Rate Brachytherapy Boosting Concurrent Chemoradiation as a Definitive Treatment Modality for Cervical Cancer: Long-term Clinical Results of Outcomes and Associated Toxicity.
Refaat T, Donnelly ED, Gentile M, Novak C, Yuan Y, Khedr GA, Helenowksi I, Lurain J, Schink J, Rademaker A, Sathiaseelan V, Strauss JB, Small W Jr. Refaat T, et al. Among authors: lurain j. Am J Clin Oncol. 2016 Apr;39(2):196-203. doi: 10.1097/COC.0000000000000035. Am J Clin Oncol. 2016. PMID: 24487420
178 results